LATEST NEWS

FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

(May 24, 2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra... Continue Reading

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

(May 23, 2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment... Continue Reading

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma

(May 21, 2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients... Continue Reading

FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches

(May 21, 2018)

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million... Continue Reading

REFERENCE AND TOOLS
LOCATIONS
Jackson Oncology Associates, PLLC
The Hederman Cancer Center
1227 North State Street, Suite 101
Jackson, MS 39202
TEL: (601)355-2485
FAX: (601)353-1463
Click Here for Map

Jackson Oncology Associates, PLLC
2368 Grove Street
Vicksburg, MS 39180
TEL: (601)638-3447
FAX: (601)630-9227
Click Here for Map
Jackson Oncology Associates, PLLC
St. Dominic Cancer Center
2969 Curran Drive North, Suite 200
TEL: (601)974-5600
FAX: (601)974-5699
Click Here for Map



Jackson Oncology Associates, PLLC
King's Daughters Hospital
427 Highway 51 North
Brookhaven, MS 39601
TEL: (601)355-2495
Click Here for Map